These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 15217555)

  • 1. Ex-vivo purging of hematopoietic progenitor cells.
    de Lima M; Shpall EJ
    Curr Hematol Rep; 2004 Jul; 3(4):257-64. PubMed ID: 15217555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo expansion of hematopoietic cells and their clinical use.
    Aglietta M; Bertolini F; Carlo-Stella C; De Vincentiis A; Lanata L; Lemoli RM; Olivieri A; Siena S; Zanon P; Tura S
    Haematologica; 1998 Sep; 83(9):824-48. PubMed ID: 9825579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ex vivo and in vivo purging for PBSCT].
    Moriyama Y
    Rinsho Byori; 1999 May; Suppl 110():79-84. PubMed ID: 10475035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo expansion of bone marrow from breast cancer patients: reduction in tumor cell content through passive purging.
    Lundell BI; Vredenburgh JJ; Tyer C; DeSombre K; Smith AK
    Bone Marrow Transplant; 1998 Jul; 22(2):153-9. PubMed ID: 9707023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
    Maki G; Tam YK; Berkahn L; Klingemann HG
    Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous bone marrow support and bone disease in metastatic breast cancer.
    Nabholtz JM; al-Tweigeri T; Jacquelin N; Venner PM
    Can J Oncol; 1995 Jul; 5(2):369-75. PubMed ID: 8853509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
    Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
    Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purging of peripheral blood progenitor cell autografts and treatment of minimal residual disease.
    Brugger W; Scheding S; Bock T; Ziegler B; Kanz L
    Stem Cells; 1997; 15 Suppl 1():159-65. PubMed ID: 9368336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An effective immunomagnetic method for bone marrow purging in T cell malignancies.
    Wang MY; Kvalheim G; Kvaløy S; Beiske K; Jakobsen E; Wijdenes J; Pihl A; Fodstad O
    Bone Marrow Transplant; 1992 May; 9(5):319-23. PubMed ID: 1617315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
    Klingemann HG; Wong E; Maki G
    Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular therapy for intensification in oncology and hematology: manipulation of peripheral blood stem-cell products].
    Douay L
    Bull Cancer; 2001 Sep; 88(9):826-32. PubMed ID: 11604353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients.
    Lillo R; Ramírez M; Alvarez A; Santos S; García-Castro J; Fernández de Velasco J; Avilés MJ; Gómez-Pineda A; Díez JL; Balas A; Vicario JL; Bueren JA; García-Sánchez F
    Cancer Res; 2002 Sep; 62(17):5013-8. PubMed ID: 12208755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
    van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
    Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative selection and protection of normal progenitor cells for autografting.
    Douay L
    Bone Marrow Transplant; 1998 Sep; 22(5):423-30. PubMed ID: 9733264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purging of peripheral blood stem cell grafts.
    Gee A
    Stem Cells; 1995 Dec; 13 Suppl 3():52-62. PubMed ID: 8747989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of immunomagnetic selection in purging autologous peripheral blood progenitor cell of breast cancer patients].
    Han X; Shi Y; Zhang W
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):203-6. PubMed ID: 11953162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is bone marrow purging proving to be of value?
    Gulati SC; Romero CE; Ciavarella D
    Oncology (Williston Park); 1994 Sep; 8(9):19-24; discussion 24, 29-32. PubMed ID: 7993723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.